SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

SANES

10.488

-0.11%↓

BBVA

19.37

+0.83%↑

BNP

89.93

+0.95%↑

CABK

11.445

+0.35%↑

INGA

26.45

+1.24%↑

Home・Listă Acțiuni・Ipsen SA.

Ipsen SA.

Închisă

SectorFinanțe

159 -1.55

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

159

Maxim

163.2

Indicatori cheie
By Trading Economics
Venit	-225M 110M
Vânzări	36M 1.9B
P/E Medie Sector	29.171 58.236
Randament dividend	0.84
Marjă de profit	5.899
Angajați	5,535
EBITDA	-171M 466M

Recomandări
By TipRanks
Recomandări	Neutru
Prognoză pe 12 luni	-9.9% downside

Dividende
By Dow Jones
Randament dividend Medie Sector	0.84% 4.64%
Următoarele câștiguri	30 iul. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	1.4B 13B
Deschiderea anterioară	160.55
Închiderea anterioară	159

Sentimentul știrilor

By Acuity

31%

69%

70 / 438 Clasament în Finance

Scor tehnic

By Trading Central

Încredere

Strong Bullish Evidence

99.85 / 104 Suport & Rezistență

Ipsen SA. Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

21 mai 2026, 22:48 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Câștiguri

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principalele dinamici ale pieței

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Câștiguri

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Achiziții, Fuziuni, Preluări

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Câștiguri

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Câștiguri

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Acțiuni populare

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Câștiguri

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Câștiguri

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Câștiguri

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Câștiguri

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Câștiguri

Stellantis Targets Distant but Constructive -- Market Talk

21 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Comparație

Modificare preț

Ipsen SA. Așteptări

Obiectiv de preț

By TipRanks

-9.9% jos

Prognoză pe 12 luni

Medie 143.8 EUR -9.9%

Maxim 170 EUR

Minim 117 EUR

În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIpsen SA. - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Neutru

5 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 5 analiști care au acordat evaluări ale acțiunilor Ipsen SA. - Dist în ultimele 3 luni.

Scor tehnic

By Trading Central

99.85 / 104Suport & Rezistență

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Sentiment

By Acuity

70 / 438 Clasament în Finanțe

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Ipsen SA.

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.